KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial.

Richard F Schlenk, Pau Montesinos, Hee-Je Kim, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Pavel Žak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Arnaud Lesegretain, Jorge Cortes, Mikkael A Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Alexander E Perl, Mark J Levis, Harry P Erba

Haematologica 110(9) 2024-2039

PMID40079105
PMCIDPMC12399959
DOI10.3324/haematol.2024.286623
发表日期2025-03-13
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

QuANTUM-First (ClinicalTrials.gov identifier: NCT02668653) was a randomized phase III trial in patients with newly diagnosed FLT3-internal tandem duplication (ITD)-positive acute myeloid leukemia (AML) treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic hematopoietic cell transplantation (allo-HCT), followed by single-agent maintenance therapy. We evaluated the impact of allo-HCT performed in first complete remission (CR1) or composite CR1 (CRc1) on overall survival (OS), considering treatment randomization. Post-hoc extended Cox regression multivariable analyses were conducted in patients who achieved complete remission/composite complete remission by the end of induction, including allo-HCT in CR1/CRc1 as a time-dependent variable to identify prognostic and predictive factors for OS. There were 297 patients with complete remission by the end of induction (quizartinib, N=147; placebo, N=150); of these, 157 (52.9%) underwent allo-HCT in CR1 (quizartinib, N=84; placebo, N=73). There were 368 patients with composite complete remission by the end of induction (quizartinib, N=192; placebo, N=176); of these, 196 (53.3%) underwent allo-HCT in CRc1 (quizartinib, N=110; placebo, N=86). Multivariable analyses revealed quizartinib treatment and allo-HCT in either CR1 (hazard ratio [HR]=0.553, 95% confidence interval [95% CI]: 0.383-0.798, P=0.0015 and HR=0.527, 95% CI: 0.349-0.796, P=0.0023, respectively) or CRc1 (HR=0.645, 95% CI: 0.470‒0.886, P=0.0068 and HR=0.557, 95% CI: 0.391-0.793, P=0.0012, respectively) as significant predictive factors for a longer OS. No new safety signals were identified. Patients who underwent protocol-specified allo-HCT in CR1/CRc1 experienced post-transplant-related complications, mostly grade ≥2 graft-versus-host disease, as expected. This post-hoc analysis further supports the use of quizartinib and allo-HCT in CR1/CRc1 as an efficacious and well-tolerated treatment strategy for newly diagnosed FLT3-ITD-positive AML patients fit for intensive chemotherapy.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 3

Figure 3. Kaplan-Meier plot of overall survival by treatment arm in patients who achieved complete remission (CR)/composite CR by the end of induction per independent review committee, by allogeneic hematopoietic cell transplantation in first CR/first composite CR. Post-hoc analysis. (A) The group of patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) a in first complete remission (CR1). (B) The group who did not undergo allo-HCT a in CR1. b (C) The group who underwent allo-HCT in first composite complete remission (CRc1). (D) The group who did not undergo allo-HCT in CRc1. b a Includes protocol-specified and non-protocol-specified allo-HCT. Some patients had both protocol-specified and non-protocol-specified allo-HCT. b Overall survival was censored at the starting date of the conditioning regimen for allo-HCT. OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval; NR: not reached; NE: not evaluable; CRc1: first composite complete remission.

A

OS

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

Figure 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

Figure 3 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 4

Figure 4. Time-dependent Simon and Makuch plot of overall survival from initial randomization by allogeneic hematopoietic cell transplantation in first complete remission (CR)/first composite CR in patients who achieved CR/composite CR by the end of induction per independent review committee. Post-hoc analysis. (A) The group who achieved CR by the end of induction. (B) The group who achieved composite CR by the end of induction. a “W/o allo-HCT in CR1” refers to patients who achieved CR without allogeneic hematopoietic cell transplantation (allo-HCT) in the study or patients who achieved CR with allo-HCT outside first CR. b “W/o allo-HCT in CRc1” refers to patients who achieved composite CR without allo-HCT in the study or patients who achieved composite CR with allo-HCT outside of first composite CR. OS: overall survival; CR1: first complete remission; CRc1: first composite complete remission; CRc: composite complete remission.

A

OS

Figure 4 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 3:extreme upward reversal曲线 4:extreme upward reversal
查看结果
B

OS

Figure 4 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 4 条,实际恢复 3 条曲线 2:off origin start曲线 2:extreme upward reversal曲线 3:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Diagram of the patients flow in the study. a Includes protocol-specified allogeneic hematopoietic cell transplantation (allo-HCT). b Includes protocol-specified allo-HCT and non-protocol-specified allo-HCT. FLT3 -ITD: FMS-like tyrosine kinase 3-internal tandem duplication; ITT: intent-to-treat; HiDAC: high-dose cytarabine; CR1: first complete remission; CRc1: first composite complete remission.
非 KM Figure
Figure 2Figure 2. Extended Cox regression analysis of overall survival, stratified by region, age, and white blood cell count. (A, B) Multivariable extended Cox regression post-hoc analysis was conducted in patients who achieved complete remission by the end of induction (A) and in patients who achieved composite complete remission by the end of induction (B), including allogeneic hematopoietic cell transplantation in first complete remission (A) and in first composite complete remission (B) as time-dependent variables and adjusted for FLT3 -ITD variant allele frequency and sex. OS: overall survival; CR: complete remission; allo-HCT: allogeneic hematopoietic cell transplantation; CR1: first complete remission; HR: hazard ratio; CI: confidence interval; FLT3 -ITD: FMS-like tyrosine kinase 3‒internal tandem duplication; VAF: variant allele frequency; ECOG: Eastern Cooperative Oncology Group; CRc: composite complete remission; CRc1: first composite complete remission.
非 KM Figure